Reuters logo
a year ago
BRIEF-Oxigene says Phase 2 study of CA4P met primary endpoint of improvement
May 24, 2016 / 10:51 AM / a year ago

BRIEF-Oxigene says Phase 2 study of CA4P met primary endpoint of improvement

May 24 (Reuters) - Oxigene Inc :

* Oxigene announces results of Phase 2 study of CA4P in recurrent ovarian cancer published in journal of clinical oncology

* Study met primary endpoint of improvement in progression free survival

* Preliminary data show improvement in overall survival of 2.6 months

* Preliminary median overall survival was longer for patients receiving CA4P combination than for control Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below